VEGFB and endothelial dysfunction: The goals were to (a) test the hypothesis that the cardiotoxic CTx agents Dox and TZM induce microvascular endothelial dysfunction and (b) provide molecular insight and proof-of-principle data regarding the potential utility of targeted VEGF-B therapy to counteract CTx-induced vascular toxicity.